Moderna (MRNA) Invested Capital (2024 - 2026)

Moderna (MRNA) has reported Invested Capital for 3 consecutive years, with $7.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital changed N/A year-over-year to $7.4 billion in Q2 2026; TTM through Jun 2026 was $7.4 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $9.2 billion, down 15.24% from the prior year.
• Invested Capital was $7.4 billion for Q2 2026 at Moderna, down from $8.0 billion in the prior quarter.
• Over five years, Invested Capital peaked at $10.9 billion in Q4 2024 and troughed at $7.4 billion in Q2 2026.
• A 3-year average of $8.9 billion and a median of $8.6 billion in 2025 frame the typical range for Invested Capital.
• The widest YoY moves for Invested Capital: up 15.24% in 2025, down 15.24% in 2025.
• Over 3 years, Invested Capital stood at $10.9 billion in 2024, then dropped by 15.24% to $9.2 billion in 2025, then dropped by 20.43% to $7.4 billion in 2026.
• The last three Invested Capital figures came in at $7.4 billion (Q2 2026), $8.0 billion (Q1 2026), and $9.2 billion (Q4 2025), per Business Quant data.